Axsome Therapeutics Inc
$
23.47
-0.7 (-2.9%)
| Volume: | 903,553 | Avg Vol (1m): | 1,288,063 |
| Market Cap $: | 781.67 Mil | Enterprise Value $: | 758.40 Mil |
| P/E (TTM): | 0.00 | P/B: | 44.62 |
| Earnings Power Value | 0.69 |
| Net Current Asset Value | 0.52 |
| Tangible Book | 0.53 |
| Projected FCF | 0 |
| Median P/S Value | 0 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 2.20 |
Cash-To-Debt ranked
higher than
56.49%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AXSM:
2.2
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.56, Med: 3.28, Max: 10000
Current: 2.2
|
| Debt-to-Equity | 1.11 |
Debt-to-Equity ranked
lower than
77.20%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
AXSM:
1.11
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -1.86, Med: 0.59, Max: 10.4
Current: 1.11
|
| Debt-to-EBITDA | -0.54 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
AXSM:
-0.54
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -2.05, Med: -0.36, Max: -0.23
Current: -0.54
|
| Piotroski F-Score | 2 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 12.74 |
DISTRESS
GREY
SAFE
| |
| WACC vs ROIC % |
ROIC 0%
WACC 21.37%
| ||
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| ROE % | -476.07 |
ROE ranked
lower than
100.00%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
AXSM:
-476.07
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -476.07, Med: -115.59, Max: -56.48
Current: -476.07
|
| ROA % | -147.12 |
ROA ranked
lower than
81.00%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AXSM:
-147.12
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -245.79, Med: -90.91, Max: -47.09
Current: -147.12
|
| ROC (Joel Greenblatt) % | -60420.61 |
ROC (Joel Greenblatt) ranked
lower than
92.37%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
AXSM:
-60420.61
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -135000, Med: -47804.83, Max: -32666.27
Current: -60420.61
|
| 3-Year Total EBITDA Growth Rate | -37.50 |
3-Year EBITDA Growth Rate ranked
lower than
83.92%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AXSM:
-4.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -113.5, Med: -39.5, Max: -4.9
Current: -4.9
|
| 3-Year EPS w/o NRI Growth Rate | -4.10 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
82.83%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
AXSM:
-4.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -29.1, Max: -4.1
Current: -4.1
|
» AXSM's 30-Y Financials
Financials (Next Earnings Date: 2019-08-08)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:AXSM
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | XMCE:IKM LSE:OPTI TSX:COM NAS:INNT ASX:CPH XCNQ:MMJ LSE:DEST WBO:MSBT TPE:1762 OSTO:CANTA TSX:HBP HKSE:03839 NAS:APVO OHEL:BIOBV XPAR:ALTHX ROCO:3205 NAS:SPHS ROCO:4192 AMEX:NAVB AMEX:NBY |
| Traded in other countries | 19X.Germany 0HKF.UK |
| Address | 25 Broadway, 9th Floor, New York, NY, USA, 10004 |
| Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 44.62 |
PB Ratio ranked
lower than
100.00%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
AXSM:
44.62
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 700.3
Current: 44.62
|
| EV-to-EBIT | -21.19 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AXSM:
-21.19
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -25.89, Med: 0, Max: 0
Current: -21.19
|
| EV-to-EBITDA | -21.22 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AXSM:
-21.22
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -25.92, Med: 0, Max: 0
Current: -21.22
|
| Current Ratio | 5.68 |
Current Ratio ranked
lower than
64.25%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AXSM:
5.68
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.51, Med: 4.11, Max: 18.63
Current: 5.68
|
| Quick Ratio | 5.68 |
Quick Ratio ranked
lower than
61.08%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AXSM:
5.68
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.51, Med: 4.11, Max: 18.63
Current: 5.68
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -12.00 |
3-Year Share Buyback Rate ranked
lower than
69.54%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
AXSM:
-12
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -26, Med: -14.6, Max: -12
Current: -12
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 44.28 |
Price-to-Tangible-Book ranked
lower than
100.00%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
AXSM:
44.28
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 2.56, Med: 5.85, Max: 123.21
Current: 44.28
|
| Earnings Yield (Joel Greenblatt) % | -4.73 |
Earnings Yield (Greenblatt) ranked
lower than
86.40%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AXSM:
-4.73
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -666.7, Med: 0, Max: 0
Current: -4.73
|
More Statistics
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 2 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |